To investigate the ferroptosis-modulating effects of cabozantinib in NSCLC, we selected lenvatinib and ripretinib as comparator VEGFR-targeting multi-kinase inhibitors with overlapping VEGFR inhibition but distinct secondary kinase profiles. This evidence concerns the gene KDR and non-small cell lung carcinoma.